ClinicalTrials.gg
RecruitingNCT07794527Updated Aug 31, 2026

Efficacy of Multiple Nerve Blocks on the Recovery of Patients Undergoing Off Pump CABG Surgeries

An interventional study of regional nerve block with local anesthesia and Placebo in Ischemic Heart Disease (IHD), Off-pump Coronary Artery Bypass and Regional Block for Pain Control, sponsored by Ain Shams University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-31.

Sponsored by Ain Shams University · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-13

Among 16 studies in Myocardial Ischemia with a site in Egypt — 3 open to participants now, 3 under way, none of them phase 3. Myocardial Ischemia · Egypt.

Started
2026
with 2 others
No phase
5 of 16
1 open now
Registered
13th of 16
by date
Lead sponsor
3 of 16
Ain Shams University

Among the 16 studies in Myocardial Ischemia with a site in Egypt, this one is one of 3 that started in 2026, is one of 5 with no phase, and was the 13th registered.

Myocardial Ischemia

1,123 studies on the registry are indexed under Myocardial Ischemia; 177 are open to participants now.

Browse Myocardial Ischemia studies →

Open to participants now

3 of the 16 studies in Myocardial Ischemia with a site in Egypt are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 135 Myocardial Ischemia studies recruiting now, 92 (68%) set no upper age limit and 6 (4%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Watch this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Myocardial Ischemia with a site in Egypt, or all of them as a file.
02

Study summary

In cardiac surgery patients , effective pain control is crucial to support early extubation, mobilization, and cognitive recovery, yet systemic opioids carry substantial risks such as respiratory depression, delirium, and delayed rehabilitation. While regional fascial plane blocks offer a safer, opioid-sparing alternative, no single technique provides complete analgesia for the complex and multi-dermatomal pain generated by sternotomy, graft harvesting, chest wall retraction, and drain sites. Therefore, a multimodal approach combining blocks such as parasternal nerve block , rectus sheath nerve block and femoral nerve block , may cover most of areas expected to be sources of intraoperative and post-operative pain in cardiac surgery patients.

03

Conditions studied

  • Ischemic Heart Disease (IHD)
  • Off-pump Coronary Artery Bypass
  • Regional Block for Pain Control

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • o Scheduled for elective off-pump coronary artery bypass graft (OPCAB) surgery via median sternotomy

    • (ASA) physical status III - IV
    • Ability to provide

Exclusion criteria

Exclusion Criteria:

  • o Emergency or redo cardiac surgery

    • On-pump CABG or concomitant valve or aortic procedures
    • Known allergy to local anesthetics or study drugs
    • Coagulopathy or ongoing anticoagulant therapy contraindicating regional block
    • Preoperative chronic opioid use or opioid dependency
    • Neurologic or psychiatric conditions interfering with pain assessment
    • Infection at the block injection site
    • Severe hepatic or renal impairment
    • (BMI) > 40 kg/m²
    • Inability to understand or cooperate with pain scoring or postoperative care.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Active comparator
    Group A (intervention)

    Patients in this group will receive standardized general anaesthesia with a preemptive bilateral superficial parasternal nerve block using 20 mL of 0.25% bupivacaine per side, in combination with a rectus sheath block (RSB) using 10 mL of 0.25% bupivacaine per side. and femoral nerve block at the side of harvesting using 10 mL of 0.25% bupivacaine.

    Procedure: regional nerve block with local anesthesia

  • Placebo comparator
    Group B ( control)

    Patients will receive standardized general anesthesia with placebo (saline) injections administered in the same anatomical planes.

    Procedure: Placebo

Interventions

  • Procedureregional nerve block with local anesthesia

    Patients will receive bilateral superficial parasternal nerve block using 20 mL of 0.25% bupivacaine per side, in combination with a rectus sheath block (RSB) using 10 mL of 0.25% bupivacaine per side. and femoral nerve block at the side of harvesting using 10 mL of 0.25% bupivacaine.

  • ProcedurePlacebo

    Patients will receive placebo (saline) injections administered in the same anatomical planes.

06

What researchers measure

Primary outcomes

  1. Time to Extubation

    Defined as the interval (in hours) from transferal to ICU to successful tracheal extubation

    Time frame: from transferal to ICU until successful tracheal extubation assessed during post operative ICU stay up to 48 hours

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Mar 2027, 6 months later.

Of 155 non-industry interventional studies with no phase under Myocardial Ischemia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 56. This study's planned 6 months is below that.

Counting every sponsor, half of 192 studies reached it within 34 months; a quarter within 15 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2026
First posted
Aug 31, 2026
StartEst.
Sep 10, 2026
Primary completionEst.
Mar 31, 2027
CompletionEst.
Apr 7, 2027
Last update
Aug 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07794527
Responsible party
Sponsor
First posted
Aug 31, 2026
Start date
Sep 10, 2026 (estimated)
Primary completion
Mar 31, 2027 (estimated)
Completion
Apr 7, 2027 (estimated)
Last update
Aug 31, 2026

Study contacts

Abdelrahman H Ashour
Contact
AbdelrahmanAshour@med.asu.edu.eg
+2-1010184467
Sherif S Sultan, MD
study director · faculty of medicine Ain Shams university

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion